Table 1.
Summarized characteristics of the selected studies in the network meta-analysis
| Study identifier References | Treatment 1 | Treatment 2 | N | Weeks | Age Mean (s.d.) | Sex (males) N (%) |
|---|---|---|---|---|---|---|
| Linagliptin Mono. (8 RCTs) | ||||||
| Del Prato et al. (2011) [31] | LIN 5 mg | PLB | 503 | 24 | 55.7 (10.2) | 243 (48.3) |
| Haak et al. (2012) [32] | LIN 5 mg | PLB | 214 | 24 | 55.95 (10.9) | 116 (54.2) |
| Kawamori (2012) [33] | LIN 5 mg | PLB | 239 | 12 | 60.0 (9.1) | 168 (70.2) |
| Barnett et al. (2012) [34] | LIN 5 mg | PLB | 227 | 18 | 56.5 (10.3) | 88(38.7) |
| Lajara (2014) [35] | LIN 5 mg | PLB | 202 | 24 | 69.1(10.0) | 122 (60.4) |
| Chen et al. (2015) [36] | LIN 5 mg | PLB | 299 | 24 | 54.3 (9.7) | 175 (58.5) |
| Taskinen (2011) [37] | LIN 5 mg | PLB | 700 | 24 | 56.5 (10.3) | 379 (54.1) |
| Inzucchi (2015) [38] | LIN 5 mg | PLB | 247 | 24 | 74.3 (3.9) | 126 (51.0) |
| Sitagliptin Mono. (13 RCTs) | ||||||
| Barzilai et al. (2011) [39] | SIT 100 mg | PLB | 206 | 24 | 72.0 (6.0) | 97(47.1) |
| Nonaka et al. (2008) [40] | SIT 100 mg | PLB | 151 | 12 | 55.3 (8.3) | 95 (62.9) |
| Aschner et al. (2006) [41] | SIT 100 mg | PLB | 491 | 24 | – | – |
| Goldstein et al. (2007) [42] | SIT 100 mg | PLB | 355 | 24 | – | – |
| Hanefeld et al. (2007) [43] | SIT 100 mg | PLB | 221 | 12 | 56.0 (8.5) | 131 (59.2) |
| Scott (2008) [44] | SIT 100 mg | PLB | 186 | 18 | 55.2 (9.5) | 106 (57.9) |
| Raz (2008) [45] | SIT 100 mg | PLB | 190 | 30 | 54.8 (9.5) | 88(46.3) |
| Charbonnel (2006) [46] | SIT 100 mg | PLB | 701 | 24 | – | – |
| Pe’rez-Monteverde et al. (2011) [47] | SIT 100 mg | PLB | 492 | 12 | – | – |
| Russell-Jones et al. (2012) [48] | SIT 100 mg | PLB | 409 | 26 | 54 | 59 |
| Nauck 2007 [49] | SIT 100 mg | PLB | 1172 | 52 | 56.7 (9.5) | 694 (59.2) |
| Arechavaleta 2011 [50] | SIT 100 mg | PLB | 1035 | 30 | 56.2 (9.9) | 563(54.4) |
| Bergenstal (2010) [51] | SIT 100 mg | PLB | 331 | 26 | 52.5 (10.5) | 165 (49.8) |
| Linagliptin Com. (4 RCTs) | ||||||
| Forst et al. (2010) [52] | LIN 5 mg + MET | PLB+ MET | 137 | 12 | 59.8 (8.9) | 81 (59.1) |
| Gallwitz et al. (2012) [53] | LIN 5 mg + MET | PLB+ MET | 1551 | 104 | 59.8 (9.4) | 933 (60.1) |
| Taskinen et al. (2011) [37] | LIN 5 mg + MET | PLB+ MET | 700 | 24 | 56.5 (10.3) | 379 (54.1) |
| Ross et al. (2012) [54] | LIN 5 mg + MET | PLB+ MET | 268 | 12 | 59.1 (10.6) | 142 (52.9) |
| Sitagliptin Com. (7 RCTs) | ||||||
| Aaboe et al. (2010) [55] | SIT 100 mg + MET | PLB+ MET | 24 | 12 | 59.8 | 17(70.8) |
| Arechavaleta et al. (2011) [50] | SIT 100 mg + MET | PLB+ MET | 1035 | 30 | 56.2 (9.9) | 563 (54.4) |
| Charbonnel et al. (2006) [46] | SIT 100 mg + MET | PLB+ MET | 678 | 24 | – | – |
| Derosa et al. (2012) [56] | SIT 100 mg + MET | PLB+ MET | 178 | 52 | 55.4 (8.4) | 86(48.3) |
| Raz et al. (2008) [45] | SIT 100 mg + MET | PLB+ MET | 190 | 30 | 54.8 (9.5) | 88(46.3) |
| Scott et al. (2008) [44] | SIT 100 mg + MET | PLB+ MET | 186 | 18 | 55.2 (9.5) | 106 (56.9) |
| Hermansen et al. (2007) [57] | SIT 100 mg + MET | PLB+ MET | 229 | 24 | 57.1 (8.8) | 120 (52.4) |